Pharmaceuticals
We offer innovative lipid excipients and personalized technical support, provided by fully trained experts to accelerate customers’ development programs, for pharmaceutical and veterinary drugs, as well as dietary supplements.
All about pharmaceuticals
-
Products
Find the most appropriate excipients for your development projects
-
Formulation technologies
Learn how to formulate with our lipid excipients
-
Human health
Excipients for pharmaceuticals
-
Animal health
Excipients for veterinary drugs
-
Nutraceuticals
Excipients for dietary supplements
-
Learn more
Our latest news and publications, on-demand webinars, and brochures.
Latest News
Une nouvelle publication qui illustre l'engagement scientifique de Gattefossé
Nous sommes heureux de partager la publication de l'article : Artificial Intelligence and Machine Learning, a Game Changer in Pharmaceutical Development? – An Updated Perspective Arising from Journées Galéniques 2024
TIM-1 as a biorelevant dynamic in vitro tool to screen lipid-based formulations
oct 2026
TIM-1, a gastro-intestinal model, is a powerful and highly biorelevant in vitro tool, closely mimicking human gastro-intestinal physiology by integrating transit, motility, pH changes, bile salt and enzyme secretions. This model enabled detailed evaluation of lipid-based formulations under dynamic conditions, providing insights that go beyond standard in vitro tests.
Tablet lipid-based drug delivery through adsorption process: development and use of a stepwise methodology
oct 2026
The study aimed to develop a methodology for selecting inert carriers to adsorb lipid-based formulations (LBFs), thereby optimizing the oral bioavailability of BCS Class II/IV APIs in tablets. Integrating a lipid matrix consisting of Labrasol ® ALF and Labrafac™ MC60 successfully modulated the release kinetics of ticagrelor, proving to be a highly effective strategy for optimized drug availability.
Development and optimization of a patient-friendly lidocaine nanoemulgel for enhanced skin permeation
oct 2026
In this study, we developed and characterized a lidocaine nanoemulgel with enhanced topical delivery performance. Nanoemulgels combine the advantages of nanoemulsions, including improved drug solubilization and skin permeation, with the favorable properties of hydrogels, such as improved skin retention, ease of application, and patient acceptability. Three excipients—Labrasol® ALF, Capryol® 90, and Transcutol® P were selected to develop nanoemulgels given their emulsifying, solubilizing, and permeation-enhancing properties.